Senju Pharmaceutical

Executive Summary

Senju Pharmaceutical, founded in 1949 in Japan, is a longstanding pioneer in ophthalmology, dedicated to developing innovative small molecule therapies for eye diseases. With a mission to advance eye care through novel mechanisms and improved formulations, the company has built a robust portfolio spanning prescription and over-the-counter (OTC) products. Its global presence, including operations in the United States, reflects a strategic commitment to addressing unmet medical needs in vision health. Leveraging decades of expertise, Senju continues to invest in R&D to deliver next-generation treatments for conditions such as glaucoma, dry eye, and retinal disorders. The company’s private status allows for long-term focus on pipeline development without quarterly earnings pressure, enabling sustained innovation in a competitive field. In recent years, Senju has intensified its clinical development efforts, with several candidates advancing through late-stage trials. The company is also expanding its commercial footprint in the US market through partnerships and direct sales. Key upcoming milestones include potential FDA submissions for a novel glaucoma therapy and phase 3 data readouts for a dry eye disease candidate. With a strong financial foundation and a focused pipeline, Senju is well-positioned to capture growth in the global ophthalmic market, projected to exceed $40 billion by 2030. Its commitment to patient-centric innovation and regulatory excellence underscores a bright outlook for near-term value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA submission for novel glaucoma therapy (SJP-001)65% success
• Q4 2026Phase 3 top-line results for dry eye disease candidate (SJP-002)70% success
• Q1 2027Potential partnership or licensing deal for US commercialization of late-stage pipeline60% success